Linda Powers Email & Phone Number

Official Northwest Biotherapeutics Corporate LinkedIn profile.Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer.The Northwest Biotherapeutics immunotherapy products are unique cancer vaccines. When compared with other active immune therapies DCVax® is more effective, longer lasting, easier to administer, can be less costly and potentially apply to all patients with the target cancers. Many experimental vaccines only apply to a limited portion of the cancer patient population and require screening of patients to determine which of them can be treated.Northwest Biotherapeutics has a deeper product pipeline, with multiple product lines and multiple target cancers already cleared for clinical trials by the FDA. The Company is unique in pursuing Europe in parallel with the US, for both our clinical trials and manufacturing.The Company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies.

Listed skills include Immunology, Biotechnology, Cancer, Cell, and 33 others.

• 

  Chief Executive Officer

  Northwest Biotherapeutics

  Jan 2008 - Present - Bethesda, Md, Us

  Ms. Powers served as Chairman of NW Bio for the last 4 years, and brings more than 25 years’ experience in corporate transactions and operations, including more than a decade specializing in building biotech companies through Toucan Capital. Ms. Powers is particularly well known for her experience in building biotech companies that are developing cell therapies, including both immune cell therapies (such as NWBio’s DCVax®) and adult stem cell therapies. Such products — consisting of living human cells — require fundamentally different manufacturing, storage, distribution and handling than do pharmaceutical drugs (“pills in bottles”). Such living cell products also involve different clinical and regulatory requirements, and different business and cost/pricing models, than traditional drugs. The cell therapy companies which Ms. Powers has been involved in building over the last decade, both in the US and abroad (in Asia, Europe and Israel), are at the forefront of clinical trials and early commercialization. Ms. Powers has served for years on a number of related boards, including the M2Gen Board of the Moffitt Cancer Center, the Board of the Trudeau Institute (a world leader in immunology research) and others. As Chairman of NW Bio, she has brought her lengthy experience to bear in helping to shape NW Bio’s overall strategy and programs. As CEO, she will now undertake operational responsibilities in addition to continuing her duties as Chairman.